applicable medical devices or medicinal products based on their primary use.

For US manufacturers entering the EU market, familiarity with the EU MDR is a mandatory prerequisite. The EU MDR, which was implemented on May 26, 2021, replaced the previous Medical Device Directive (MDD) and establishes stringent requirements on design, production, and post-market surveillance.

• US Regulations: Governed by the Federal Food, Drug, and Cosmetic Act (FDCA). The FDA delineates between drugs, biologics, and devices.
• EU Regulations: Governed by the EU MDR, which places clear emphasis on risk management and post-market responsibilities.

Understanding the classification of your product is the first step. Determining if your combination product is primarily a drug or device will dictate the regulatory pathway you must follow.

Step 2: Classification of Combination Products

Correct classification is vital as it influences the regulatory submission process and required documentation. In the EU, the classification process considers the intended use and mode of action, evaluating whether the product qualifies as a device, a drug, or both:

• Determine the primary intended purpose of the combination product.
• Consult the relevant guidance documents from the European Medicines Agency (EMA) for classification rules.
• Consider any supporting documentation that can substantiate claims regarding the device’s functionality.

In the US, the FDA classification system includes 3 classes (Class I, II, or III) based on risk assessment and intended use, which also applies to combination products. Manufacturers should utilize the FDA’s formal classification guidance documentation before beginning the regulatory submission process.

Establishing the correct classification upfront influences everything downstream, from clinical evaluation to market surveillance responsibilities.

Step 3: Preparing the Technical Document Dossier for EU MDR Compliance

The technical documentation dossier serves as an essential artifact in demonstrating conformity to the EU MDR. For combination products, the formation of this dossier requires adherence to Annex II of the EU MDR alongside relevant GSPR (General Safety and Performance Requirements). Key components include:

• Device Description: Provide a description of the product, intended use, and its components.
• Conformity Assessment: Identify the Notified Bodies that will conduct the review and ensure compliance with applicable EN standards and ISO regulations.
• Clinical Evaluation: Develop a thorough clinical evaluation plan that demonstrates safety and efficacy, which is particularly critical for combination products.
• Risk Management: Implement a risk management plan compliant with ISO 14971 to identify and mitigate potential risks to patients.
• Post-market Surveillance Plan: Outlining post-market evaluation mechanisms aligned with the requirements of Article 117 and respective GSPR provisions.

The comprehensive preparation of this dossier is crucial, as it will be the foundation for the Conformity Assessment procedure initiated with your Notified Body prior to market entry in the EU. Ensuring completeness and accuracy of the dossier can significantly reduce the likelihood of extensive queries and improve the chances of successful approval.

Step 4: Engaging with Notified Bodies

In the EU context, Notified Bodies play a critical role in validating compliance with the EU MDR. Manufacturers must initiate a partnership early if they intend to bring combination products to market:

• Select Appropriate Notified Body: Choose a Notified Body that has the necessary scope for the product classification. Verify accreditation status with the NANDO database.
• Plan for Communication: Establish a transparent dialogue early on to align expectations and clarify requirements.
• Documentation Requirements: Ensure that all reports, clinical data, and technical documentation are prepared to align with Notified Body requirements.
• Audits and Assessments: Prepare for both initial and periodic audits, keeping in mind that Notified Bodies will conduct on-site assessments of manufacturing sites under their supervision.

The collaboration with Notified Bodies is not just procedural. It is vital for advancing product lines and for maintaining momentum in the regulatory process.

Step 5: Regulatory Submission Process

The submission process differs significantly when comparing submissions to the FDA and EU requirements. In the US, manufacturers can submit through a 510(k), PMA, or NDA, depending on the classification of the combination product:

• 510(k) Submission: Often requires evidence of substantial equivalence with a legally marketed device.
• PMA Application: Mandated for Class III products, necessitating extensive clinical data.

For the EU submissions, manufacturers must ensure that they have completed all necessary documentation before applying for CE marking, which is validated through the selected Notified Body. Key submission milestones include:

• Compilation and submission of the Technical Documentation.
• Preparation and submission of the Clinical Evaluation Report.
• Application for CE marking, accompanied by the Declaration of Conformity.

Properly following through with each step in the submission process is imperative to expedite approvals and maintain regulatory compliance.

Step 6: Navigating EUDAMED Registration and Reporting

The European Database on Medical Devices (EUDAMED) improves transparency and maintains a comprehensive record of devices in the EU market. All manufacturers of combination products must safeguard compliance with EUDAMED regulations that include registration of devices, clinical investigations, and vigilance reporting.

• Registration: All manufacturers and products must be registered within EUDAMED prior to market entry, mapping the appropriate classes and categories.
• Vigilance Reporting: Establish structured procedures for vigilance and adverse event reporting aligned with EU’s MEDDEV guidance.
• Continuous Updates: Update EUDAMED actively to ensure the database reflects the latest information related to your combination products.

Failure to appropriately register or update information can result in fines and penalties, complicating ongoing market presence.

Step 7: Post-Market Surveillance and Commitments

Once market authorization is achieved, both the EU and US regulatory environments demand robust post-market surveillance programs to monitor product performance and safety:

• Ongoing Monitoring: Implement a system for continuous data collection to analyze the safety profile of your combination product.
• Risk Management Review: Regularly update the Risk Management Plan based on post-market performance data.
• Periodic Safety Update Reports (PSUR): Prepare and submit PSURs as required by the EU regulations.

Creating effective mechanisms for post-market surveillance will aid manufacturers in sustaining compliance and adapting quickly to any emerging issues.

Conclusion: Establishing a Global Regulatory Strategy

Current trends indicate that US manufacturers need to establish an integrative global strategy that not only incorporates compliance with US regulations but also comprehends and aligns with the rigorous demands of the EU MDR. By understanding classification pathways, preparing appropriate technical documentation, and engaging with Notified Bodies, manufacturers can position themselves favorably in this complex regulatory environment. Leveraging EU MDR consulting services can further streamline the process, ensuring compliance and enhancing product success across international markets.